The global atrial fibrillation drugs market size is expected to reach around US$ 17.5 billion by 2026 with a CAGR around 3.4 % throughout the forecast period 2019 to 2026.
Atrial fibrillation drugs is a fast and irregular heart rate which increases risk, such as discomfort (angina), pressure, or chest pain that leads to congestive heart failure. Atrial fibrillation drugs is a fast or irregular heart rate. Atrial fibrillation drugs symptoms include perplexity, dizziness, fatigue and disappearance.
The report provides analysis of global Atrial fibrillation Drugs market for the period 2015-2026, wherein 2019 to 2026 is the forecast period and 2018 is considered as the base year.
During the forecast period, the market in atrial fibrillation drugs medicines is expected to be profitably increasing. Increasing geriatric population rates combined with increased valvular disease prevalence will increase market growth. In addition, the increased rate of diabetic populations also contributes to the growth of the market for atrial fibrillation drugs. The increasing prevalence in developing and some developed countries of cardiovascular diseases due to an increase in sedentary lifestyles and an increase in habits of binge eating. However, one of the main reasons for the barrier to adoption in few developing and underdeveloped countries will be the side effects of drugs. Drug-negative effects such as severe bleeding, fatigue, and so on will continue to interfere with market growth over time. Furthermore, lack of awareness on recent medical drug therapies in some emerging regions may hamper market growth in atrial fibrillation drugs treatments.
Over the estimated period, the market for anticoagulants is expected to grow by 3.4 percent. The rate of stroke in people with Atrial fibrillation was known to decline for many years now. Maximum thromboembolic disturbances of atrial fibrillation drugs with oral anticoagulants are mostly preventable. For more than fivety years, vitamin K antagonists have been the only effective therapeutic option for prevention of atrial fibrillation drugs. Moreover, manufacturers ' increasing focus on the development of oral anticoagulants has increased demand for the products. The above reasons will therefore increase the growth of the market in anticoagulants. The market for antiarrhythmic drugs in atrial fibrillation drugs was estimated to decline by more than $1.3 million in the near future due to a lower efficiency in the restructuring and maintenance of normal cardiac rhythms. It is evident that people over 65 years of age often experience heart rhythm disorders, and thus the most preferred solution for the older population is antiarrhythmic treatment. The appearance of more effective oral anticoagulants will, however, gradually replace the use of antiarrhythmic drugs in auricular fibrillation. Therefore, in the near future, the market for antiarrhythmic drugs will gradually decline in atrial fibrillation drugs.
In 2018 there were an estimated USD 7,000 million in the use of atrial Fibrillation drugs in paroxysmal condition. Paroxysmic atrial fibrillation occurs when a sudden and fast heart rate begins and stops all of a sudden within a couple of days. Currently around 2.8 to 6.1 million Americans are affected by some type of atrial fibrilation according to the American Heart Association. The probability of atrial fibrillation is increased with age. While atrial fibrillation is paroxysmal, it can not threaten life, but with time it can have critical consequences. Blood thinners or anticoagulants thus increase the growth of atrial fibrillation drugs on the market are the most suitable treatment presribed for paroxysmal atrial fibrillation. In the coming years, the use of atrial fibrillation medicines for persistent disease will grow by 3.2 %. The most common heart rhythm is atrial fibrillation, and persistent atrial fibrillation is a condition in which erratic and rapid heartbeat lasts for a longer time than paroxysmal. Antiarrhythmic or anticoagulant agents are the most preferable treatment in these situations, thus contributing to restoring regular heart beatings and prevention of blood clots.
During 2018, the use of atrial fibrillation drugs was estimated to be around USD 3 billion. In order to improve quality of life, a lot of the patients with auric fibrillation require restore their sinus rhythm. In patients with atrial fibrillation, maintenance and acute restore of sinus rhythms are referred to as rhythm control. A first line therapy, and medication are usually recommended based on the absence or presence of a structural cardiac disorder or heart failure, renal function and other comorbidities, is an antiarrhythmic drug. The increase in geriatric population has been shown to boost demand for atrial fibrillation medicines because they are more prone to cardiac rhythm disturbances.
In 2018, the market for the oral atrial fibrillation medicinal products was worth about USD 10 billion. The prevalence of auric fibrillation worldwide is growing rapidly, especially as the population age grows. Thromboembolic patients have greater morbidity, mortality and longer hospital stays compared to patients with other types of stroke due to atrial fibrillation. Oral therapy due to its effectiveness in preventing blood clotting, thus, increasing market growth, is the most prescribed pharmaceutical therapy to prevent atrial stroke. During the projected period, a significant increase in the injectable atrial fibrillation drugs segment is expected. The growth in patients with auric fibrillation who cannot take drugs verbally is due to their extensive use. Consequently, the growth of injectable atrial fibrillation drugs in such circumstances has increased.
End Use Stance
Atrial medication in hospitals, which leads to large market shares, is most commonly used. Around $6.5 billion in 2018 was generated by the hospital segment. A large share of atrial fibrillation medication therapies take place in hospitals; the demand for these medicines is therefore highest. The hospital end-use sector will continue to lead over the forecast period, as drug therapies are increasingly available in hospital settings, together with the increased drug supply agreements between production companies and hospitals. In 2018, cardiac centers were the most preferred location in both developed and developing countries and held an important share of the industry. The segment of cardiac centers is expected to expand by 4% during the projected period in a healthy CAGR. Accordingly, oral drug therapy should encourage growth of industry in cardiac centres.
The United States dominated the North American market for atrial fibrillation drugs with around 5 million dollars in 2018. The USA has captured the world's largest share because of the growing geriatric population and the increasing prevalence of valve diseases within the population. In addition, the growth of the U.S. atrial fibrillation market will continue with an ever increasing number of drug manufacturers, such as Johnson and Johnson and Bristol-Myers Squibb.
Over the forecast period, China is expected to see atrial fibrillation drug market rapid growth of 6.3 %. The development of hospitals and the increasing acceptance of local private clinics are all attributable to growth. In addition, the prevalence of heart disease due to a sudden lifestyle transition and increasing binge eating have enhanced the growth of the industry.
Global Atrial Fibrillation Drugs Market, by Product
Global Atrial Fibrillation Drugs Market, by Type
Global Atrial Fibrillation Drugs Market, by Application
Global Atrial Fibrillation Drugs Market, by Route Of Administration
Global Atrial Fibrillation Drugs Market, by End Use
Global Atrial Fibrillation Drugs Market, by Geography
The market research study on “Atrial Fibrillation Drugs Market - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026” offers detailed insights on global Atrial fibrillation Drugs market segments with market dynamics and their impact. The report also covers basic technology development policies.
Key Players & Strategies
The major industrial operators in the global market are Johnson & Johnson, Pfizer, Sanofi, Bayer AG, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo and AstraZeneca. Due to their strong financial position and better brand recognition these key market players hold majority market share. These firms’ main strategies in the market include launching of new products, expansion strategy, procurement strategy, and other measures to achieve a competitive advantage over their peers.